Latest Breaking News On - Candice long - Page 1 : vimarsana.com

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.

Jersey
David-lee
Johnson
None-of-cilag-holding
Janssen-research-development
Janssen-biotech-inc
Cilag-holding
Numab-therapeutics
Global-immunology-therapeutic-area-head
Johnson-innovative
Candice-long
Worldwide-vice-president

J&J gains another bispecific antibody with $1.25B skin drug buy

BioPharma

Jersey
Switzerland
Swiss
Abbvie-rinvoq
Regeneron-dupixent
Ambrx-biopharma
Johnson
Novo-holdings
Boehringer-ingelheim
Dive-brief
Yellow-jersey-therapeutics
Candice-long

J&J scoops up another atopic dermatitis drug for $1.25B

J&J scoops up another atopic dermatitis drug for $1.25B
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Jersey
Michael-bauer
Johnson
Novo-holdings
Novo-holdings-partner
Numab-therapeutic
Yellow-jersey-therapeutics
Yellow-jersey
Holdings-partner
Candice-long

J&J: towards acquisition of Proteologix for $850 million

J&J: towards acquisition of Proteologix for $850 million
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Johnson
Integrating-proteologix
Candice-long
Global-vice-president

J&J acquires Proteologix for $850M, adds bispecific antibodies to pipeline

The Proteologix deal marks the second big pharma buy for J&J in 2024, following its acquisition of Amrbx Biopharma earlier this year.

Ambrx-biopharma
David-lee
Johnson
Candice-long